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Abstract
Background and aims
Biomarkers reflecting disease activity and prognosis in primary sclerosing cholangitis (PSC) have not been firmly established. Enhanced Liver Fibrosis (ELF) test was previously reported to predict outcome in PSC. We aimed to validate the prognostic utility of ELF test in an independent, multicenter, retrospective PSC study population.
Methods
We collected serum samples from PSC patients from seven countries. We estimated rates of transplant-free survival by the Kaplan-Meier method, used Cox proportional hazards regression to explore the association between ELF test and clinical outcome and determined prognostic performance of ELF test by computing the area under the receiver operating characteristic (AUC-ROC) curve.
Results
The final analysis included 534 PSC patients (61% males). Features of autoimmune hepatitis or concomitant inflammatory bowel disease affected 44 (8%) and 379 (71%) patients, respectively. ELF test levels were higher in patients reaching the combined endpoint liver transplantation or death (median 10.9 [interquartile range (IQR) 9.8- 
Conclusion
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Our retrospective data validates the predictive utility of ELF test for clinical outcomes in PSC. The clinical utility of biomarkers for fibrosis in patients with PSC should be assessed in prospective patient cohorts.
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Key Points
• Primary sclerosing cholangitis (PSC) is a progressive biliary disease lacking medical treatment with currently no established tools to predict prognosis in the individual patient. The lack of biomarkers for risk stratification is an important obstacle to the development of therapy.
• The Enhanced Liver Fibrosis (ELF ® ) test was previously reported to predict clinical outcome in two Norwegian PSC cohorts independently of clinical risk scores.
• Our data confirm, in a large, international, multicenter cohort, that ELF test predicts prognosis in PSC and may be used for risk stratification in clinical follow-up.
• Combining ELF test with clinical prognostic scores may add incremental prognostic value.
INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease of unknown etiology resulting from the development of fibrotic strictures throughout the biliary tree. Eventually most patients develop fibrosis, cirrhosis and end-stage liver failure. [1] The only curative treatment modality is liver transplantation, [2] and PSC is the number one indication of liver transplantation within the spectrum of autoimmune and cholestatic liver disease. [3] There is an unmet need for medical therapeutic options in the management of PSC patients. However, the development of new treatment strategies is hampered by the lack of prognostic markers and the overall slowly progressive nature of the disease, which results in difficulties to demonstrate treatment effects in clinical trials. [4] Liver fibrosis is a well-established predictor of disease outcome in PSCexemplified by the implementation of liver histology and liver elastography in several prognostic models for PSC. [5] [6] [7] [8] [9] Over recent years, non-invasive methods to measure liver fibrosis have gained interest, including the use of serum biomarkers. The
Enhanced Liver Fibrosis (ELF) test is a promising panel, incorporating three direct serum markers of fibrosis in an algorithm: hyaluronic acid, tissue inhibitor of metalloproteinases-1 (TIMP-1), and amino-terminal pro-peptide of type III procollagen (PIIINP). [10, 11] The ELF test accurately predicted significant liver fibrosis and furthermore predicted clinical outcome in several independent populations and in patients with various etiologies of chronic liver disease. [12] [13] [14] [15] [16] Recently, the prognostic value of the ELF test in PSC was assessed in two independent Norwegian PSC cohorts. [17] The ELF test consistently predicted liver transplant-free survival in PSC patients independently of other risk factors or risk scores. [17] In the present study, we aimed to validate the prognostic value of the ELF test in a large, multi-center PSC cohort. Rates of transplant-free survival were estimated for three groups of fibrosis severity: mild, moderate and severe fibrosis defined as ELF test level <7.7, ≥7.7 to <9.8, and ≥9.8, respectively, as recommended by the manufacturer; crude risk was compared using log-rank test. Due to the small number of patients with a follow-up longer than 60 months (n=37 out of 516), survival curves were truncated at 60 months.
PATIENTS AND METHODS
Study
Univariable Cox proportional hazards model was used to assess the potential association of all clinical and biochemical variables with the occurrence of the endpoint. Factors that were significantly associated (P<0.05) with outcome in the univariable analysis were entered into the multivariable model. Using stepwise forward multivariable Cox regression analysis, the independent prognostic value of ELF test was assessed. The criterion for retaining predictors was a p-value <0.05.
The proportionality during follow-up for risk prediction with ELF test as a continuous variable was found acceptable for all assays and cohorts as tested by the cox.zph function in R.
The prognostic performance of ELF test was determined by computing the area under the receiver operating characteristic (ROC) curve. The optimal threshold to distinguish patients that experience an endpoint from those that do not, was calculated by Youden's index -the maximum total sensitivity and specificity.
Correlations between ELF test and other laboratory variables were assessed by Spearman's rank correlation test.
Statistical analyses were performed using SPSS version 22.0 software (SPSS, Chicago, IL); calculation of the net reclassification index and testing for the proportional hazards assumptions were performed in R (R Foundation for Statistical
Computing, Vienna, Austria). p<0.05 was considered statistically significant. 
RESULTS
Patient characteristics
Prognostic performance of the ELF test
The manufacturer of the ELF test defines three groups of fibrosis severity based on ELF scores, i.e. none to mild, moderate, and severe (ELF score <7.7, ≥7.7 to <9.8 and ≥9.8, respectively). There was a significant association between the ELF test subdivided into three groups based on these definitions (N=81 mild, 257 moderate and 178 severe fibrosis, respectively), and the risk of reaching the clinical composite endpoint all cause death and liver transplantation, p<0.001 (Figure 1 ). Additional
Kaplan-Meier survival analysis when applying the composite endpoint PSC related death and liver transplantation showed a comparable result (Supplementary Figure   1 p=0.039).
The ELF test had a good discriminative ability to distinguish patients that reach (Suppl. Fig. 2 ).
Clinical and biochemical prognostic indicators of transplant-free survival
Univariable Cox regression analysis showed a significant association between transplant-free survival and the following variables: sex, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, albumin, international normalized ratio, platelet count, AST to platelet ratio index (APRI), and the ELF test ( Table 3 ).
In addition to the ELF test, total bilirubin and albumin remained independently associated with outcome in multivariable analysis (Table 3) .
DISCUSSION
This study confirms the prognostic value of ELF test in the prediction of clinical outcome in PSC, in a large, well characterized, multicenter PSC cohort. We found that the ELF test was a strong predictor of clinical outcome as defined by liver transplantation or death independent of other clinical and laboratory variables associated with outcome. One unit increase in the ELF test was associated with a 1.31-fold increased risk of death or liver transplantation.
By subdividing ELF test results into three groups of fibrosis severity based on cut-off levels provided by the manufacturer, we showed that patients with PSC can be stratified into low, intermediate and high risk groups for the composite endpoint of death or liver transplantation. Although the difference between these three groups was statistically significant, a comparison of the Kaplan-Meier curves of the present study with the original results, suggested a suboptimal ability to distinguish mild from moderate disease. [17] This may in part be explained by the use of thresholds not originally developed to differentiate disease stages in a biliary disorder with a portoportal fibrosis pattern like PSC. However, the manufacturer's optimal cut-off to discriminate between patients with and without severe fibrosis (9.8) was similar to the optimal cut-off value to discriminate between patients that do and do not reach an endpoint as estimated by the Youden's index in our study population (9.85) and seems to be a robust cut-off level to identify high-risk patients. Previously, higher optimal cut-off values for ELF of 11.1 and 11.2 were identified in two PSC populations; [17] application of any of these cut-off levels in the present study population yielded increased specificity at the cost of reduced sensitivity compared to a cut-off of 9.8. Further studies should aim to define clinically meaningful PSCspecific cut-off levels that might also robustly identify a low-risk group.
We report increased ELF test in patients later diagnosed with CCA (n=10) in line with previous results. [17] The ELF test was not significantly increased in five patients who had a diagnosis of CCA at serum withdrawal for ELF test analysis.
Excluding patients with CCA from the analyses did not alter the association of ELF test with clinical outcome (data not shown). The present data cannot resolve the question of whether the association between ELF test and CCA in PSC reflects more advanced disease in these patients or results from the excessive fibrotic response in the surrounding tissue of the "scirrhous" type of CCA often found in PSC, potentially an early risk sign for CCA. [20, 21] Dedicated analyses seem warranted to further explore the association between ELF test and CCA.
In addition to the ELF test, several other established biomarkers of fibrosis have been used in other liver diseases, including the APRI score, [22] Fibrosis-4-score, [23] and FibroTest. [24] The diagnostic performance of these biomarkers along with ELF test and liver histology was assessed in a PSC patient population that was included in a randomized trial of simtuzumab. [25] The ELF test accurately diagnosed advanced fibrosis and cirrhosis (sensitivity 97% and 79%, specificity 9% and 64%, respectively) whereas FibroTest, APRI and FIB-4 scores all had lower sensitivities (ranging 17-58%) and their main value was in excluding advanced fibrosis and cirrhosis. [25] These results corroborate previous findings showing that baseline APRI and FIB-4 did not identify patients with higher risk of developing liver related events while ELF test did. [16] The most widely used prognostic model in PSC research is the Mayo Risk model; however, this model notably failed to predict adverse outcomes in high-dose ursodeoxycholic acid studies. We could not compare ELF test to the Mayo risk score because of lack of reliable data on variceal bleeding. However, our data show that the ELF test predicted clinical outcome independently of all individual biochemistries identified as relevant through univariable analyses. These findings suggest that ELF test has an independent prognostic value, and that the combination of the ELF test and clinically derived prognostic models in PSC might increase prognostic power.
Such composite models warrant further research. As PSC in its early stages primarily is an inflammatory disease of the biliary epithelium, it would be interesting to assess whether addition of an inflammatory marker would improve prognostication in the low-risk groups defined by ELF. Furthermore, it would be interesting to explore whether compound assessments combining ELF test with ultrasound-or MR-based liver stiffness measurements, could provide incremental prognostic information.
Whether the ELF test reflects merely fibrosis stage or also disease intensity has not been firmly established. The original paper on the development of the ELF test describes excellent correlation between ELF test and degree of fibrosis, but only moderate correlation with histological grade, suggesting that it is mostly a stage marker. [10] Exploring the dynamics of ELF test results over time, as well as its ability to measure treatment effect in terms of fibrosis regression is warranted to establish the ELF test's applicability in clinical practice and its usefulness to function as a potential surrogate endpoint in clinical trials in PSC.
Proving the clinical value of a new test, and deciding when and how to implement a new test in clinical practice are important challenges. To be clinically useful, a biomarker should be measurable by available, reliable analytical methods, add new information compared to existing markers, and guide patient management. [26] The pivotal criterion is the consistency and strength of the association between the biomarker and the outcome, and the extent to which the new marker improves prognostication by addition to or replacing established tools.
External validation in at least two adequately-sized prospective studies is advised for prognostic markers in cardiac disease. [26] The ELF test is commercially available and well validated for other liver diseases. [14] [15] [16] Furthermore, ELF test has shown consistent, strong association with clinical outcome independent of clinical risk models in two independent monocenter PSC panels, and now in a large, multicenter PSC patient panel. [17] The ELF test has shown incremental value when added to the clinically based Mayo risk score. However, prospective validation is lacking and further comparisons and combinations with other biomarkers and risk scores merit investigation before implementation of ELF in clinical practice.
The retrospective nature and the lack of radiological or histological staging represent limitations to the present study. The choice of all-cause death and liver transplantation as combined end-point may also introduce elements of uncertainty based on variable indications for liver transplantation. However, in lack of gold standards, clinical outcome is a valid variable against which ELF can be benchmarked. Assessment of the dynamics of the ELF test over the disease course was not feasible because of the cross-sectional design of this study.
In conclusion, our data from a large, international, multicenter cohort confirm the prognostic value of the ELF test and its ability to stratify risk of poor outcome in 
